Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00884312 · ClinicalTrials.gov registry record · Phase 2
A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT00884312 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 101 participants.
The verdict
NCT00884312, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, Phase 2 study of carfilzomib to monitor the safety and efficacy of long-term or continuing carfilzomib therapy for patients who previously completed a primary carfilzomib treatment study.
Interventions
- DRUG Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2009-04-09 |
| Est. Completion | 2017-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00884312
The ClinicalTrials.gov registry entry for NCT00884312 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Carfilzomib is the first listed.
NCT00884312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00884312 about?
NCT00884312 is a clinical study titled "A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols". This is a multi-center, open-label, Phase 2 study of carfilzomib to monitor the safety and efficacy of long-term or continuing carfilzomib therapy for patients who previously completed a primary carfilzomib treatment study.
What is the current status of trial NCT00884312?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2009-04-09. Estimated completion is 2017-05-17.
What interventions are being tested in trial NCT00884312?
The interventions under investigation include: Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT00884312?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.